Therefore, we have constructed a network between SGLT2 inhibitors and targets related to CKD, T2DM, and HF and analyzed the potential mechanisms of SGLT2 inhibitors' cardioprotective effects through network pharmacology, which contributes to deepening the understanding of SGLT2 and provide a theoretical for future studies. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.